Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

[FDG-PET].

Tashiro M.

Nihon Rinsho. 2011 Oct;69 Suppl 8:525-9. Japanese. No abstract available.

PMID:
22787844
2.

Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease.

Foster NL, Wang AY, Tasdizen T, Fletcher PT, Hoffman JM, Koeppe RA.

Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S29-36. doi: 10.1016/j.jalz.2007.10.004. Epub 2007 Dec 21. Review.

PMID:
18631997
3.

Simultaneous demonstration of metabolic lesions consistent with Alzheimer disease and brain metastases on FDG-PET imaging.

Takalkar AM, El-Haddad G, Lilien DL, Patterson JC 2nd.

Clin Nucl Med. 2008 Jun;33(6):438-40. doi: 10.1097/RLU.0b013e31817082c2. No abstract available.

PMID:
18496460
4.

Advantage of late scanning in brain 18F-FDG PET.

Ishii K.

J Nucl Med. 2006 Apr;47(4):729; author reply 729. No abstract available.

5.

Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments.

Reiman EM; Alzheimer's Disease Biomarkers Working Group for the Alliance for Aging Research.

Neurobiol Aging. 2011 Dec;32 Suppl 1:S44-7. doi: 10.1016/j.neurobiolaging.2011.09.007. Epub 2011 Oct 7. Review.

6.

PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- for.

Ishii K, Minoshima S.

Eur J Nucl Med Mol Imaging. 2005 Dec;32(12):1463-5. No abstract available.

PMID:
16283181
7.

PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- against.

Pupi A, Nobili FM.

Eur J Nucl Med Mol Imaging. 2005 Dec;32(12):1466-72. No abstract available.

PMID:
16283180
8.

Concordance between (99m)Tc-ECD SPECT and 18F-FDG PET interpretations in patients with cognitive disorders diagnosed according to NIA-AA criteria.

Ito K, Shimano Y, Imabayashi E, Nakata Y, Omachi Y, Sato N, Arima K, Matsuda H.

Int J Geriatr Psychiatry. 2014 Oct;29(10):1079-86. doi: 10.1002/gps.4102. Epub 2014 Mar 29.

PMID:
24687634
9.

[Positron emission tomography: contribution to diagnosis of dementia and development of disease-modifying drugs].

Ito K, Kato T.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2009 Aug;29(4):153-60. Review. Japanese.

PMID:
19764482
10.

Visual-statistical interpretation of (18)F-FDG-PET images for characteristic Alzheimer patterns in a multicenter study: inter-rater concordance and relationship to automated quantitative evaluation.

Yamane T, Ikari Y, Nishio T, Ishii K, Ishii K, Kato T, Ito K, Silverman DH, Senda M, Asada T, Arai H, Sugishita M, Iwatsubo T; J-ADNI Study Group.

AJNR Am J Neuroradiol. 2014 Feb;35(2):244-9. doi: 10.3174/ajnr.A3665. Epub 2013 Aug 1.

11.

Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment.

Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y.

Int J Clin Pract. 2012 Feb;66(2):185-98. doi: 10.1111/j.1742-1241.2011.02845.x. Review.

PMID:
22257044
12.

MR, (18)F-FDG, and (18)F-AV45 PET correlate with AD PSEN1 original phenotype.

Saint-Aubert L, Payoux P, Hannequin D, Barbeau EJ, Campion D, Delisle MB, Tafani M, Viallard G, PĂ©ran P, Puel M, Chollet F, Demonet JF, Pariente J.

Alzheimer Dis Assoc Disord. 2013 Jan-Mar;27(1):91-4. doi: 10.1097/WAD.0b013e318251d87c.

PMID:
22517194
13.

CMS issues new instructions on PET coverage.

[No authors listed]

J Nucl Med. 2014 Apr;55(4):9N-10N. No abstract available.

14.

Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial.

Wang T, Huang Q, Reiman EM, Chen K, Li X, Li G, Lin Z, Li C, Xiao S.

J Clin Psychopharmacol. 2013 Oct;33(5):636-42. doi: 10.1097/JCP.0b013e31829a876a.

PMID:
23948786
15.

Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease.

Kawachi T, Ishii K, Sakamoto S, Sasaki M, Mori T, Yamashita F, Matsuda H, Mori E.

Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):801-9. Epub 2006 Mar 21.

PMID:
16550383
16.

FDG-PET for early assessment of Alzheimer's disease: isn't the evidence base large enough?

Lucignani G, Nobili F.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1604-9. doi: 10.1007/s00259-010-1535-9. Review. No abstract available.

PMID:
20582541
17.

Topographic patterns of brain functional impairment progression according to clinical severity staging in 116 Alzheimer disease patients: FDG-PET study.

Choo IH, Lee DY, Youn JC, Jhoo JH, Kim KW, Lee DS, Lee JS, Woo JI.

Alzheimer Dis Assoc Disord. 2007 Apr-Jun;21(2):77-84.

PMID:
17545731
18.

Frontal dysfunction underlies depressive syndrome in Alzheimer disease: a FDG-PET study.

Lee DY, Choo IH, Jhoo JH, Kim KW, Youn JC, Lee DS, Kang EJ, Lee JS, Kang WJ, Woo JI.

Am J Geriatr Psychiatry. 2006 Jul;14(7):625-8.

PMID:
16816017
19.

Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.

Vallabhajosula S.

Semin Nucl Med. 2011 Jul;41(4):283-99. doi: 10.1053/j.semnuclmed.2011.02.005. Review.

PMID:
21624562
20.

Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls.

Newberg AB, Arnold SE, Wintering N, Rovner BW, Alavi A.

J Nucl Med. 2012 Jun;53(6):902-7. doi: 10.2967/jnumed.111.099606. Epub 2012 May 10.

Supplemental Content

Support Center